CREATION OF ANTI-PAD4 ANTIBODY PHARMACEUTICAL

摘要

A novel antirheumatic drug is provided. An antibody that specifically binds to a polypeptide containing at least six consecutive amino acids from amino acid sequence number 2 or 4. A pharmaceutical composition that contains said antibody, an anti-peptidylarginine-deiminase-4 antibody, or a combination thereof; an antirheumatic drug; and a peptidylarginine deiminase 4 inhibitor. Also, an antigen peptide, namely a polypeptide that contains at least six consecutive amino acids from amino acid sequence number 2 or 4.